Th e success of the current anti-Helicobacter pylori (H. pylori) treatment protocols is reported to decrease by years, and research is needed to strengthen the H. pylori eradication treatment. 
INTRODUCTION
Successful treatment of Helicobacter pylori (H. pylori) generally requires the use of several antibacterial agents simultaneously. With the exception of a limited number of studies, increasing clarithromycin resistance causes the decline in eff ectiveness of the legacy triple therapy (i.e., a proton pump inhibitor [PPI] , clarithromycin and amoxicillin) and intention to treat (ITT) eradication rates have been reported lower than 80 (grade F) in several studies [1] .
Th e impact of resistance can be minimized by addition of a second, third or even the fourth drug for killing the few remaining organisms or administrating drugs in diff erent time intervals leading to a high cure rate. With the decrease in the success of standard triple treatment, new treatment protocols have been developed. Sequential therapy (ST) (amoxicillin 1 g plus a PPI b.i.d. for 5 days, then clarithromycin 500 mg and tinidazole or metronidazole 500 mg b.i.d plus a PPI b.i.d for remaining 5 days) has been developed a decade ago as one of the promising therapeutic approach to solve this problem [2] and has been shown to be superior to legacy triple therapy even if there has been clarithromycin resistance [1] . However, up to now, reported cure rates of the original ST did not exceed above Grade B (90-95) in ITT analysis. Moreover, recent studies from diff erent countries have reported disappointing results with ST [3] [4] [5] [6] . It is of interest whether additional changes in ST may cause further improvement in eradication rates or not.
Bismuth is cytoprotective and antibacterial agent which has been safely used for three centuries. Th e addition of bismuth compounds to diff erent antibiotic combinations have been reported to provide a favorable eff ect on eradication rates [7] [8] [9] . Th ere is no data on eradication rates with original ST plus bismuth in the literature. We aimed to compare eradication rates of ST with and without bismuth as a fi rst-line therapy.
MATERIALS AND METHODS

Subjects
Th is prospective, single-center study that was performed at the Gastroenterology Department of Kecioren Education and Research Hospital in Turkey in 2013. Th is trial was approved by Institutional Review Board.
Between February 2013 and July 2013, patients with dyspepsia were considered eligible for the study if they underwent upper gastrointestinal endoscopy, and H. pylori infection was diagnosed through histologic examination (Giemsa stain) of antral and body biopsy samples diagnosed histopathologically documented H. pylori infection. Patients were considered infected by H. pylori if resulted positive. Exclusion criteria included (1) previous attempt of H. pylori eradication therapy; (2) recent use of antibiotic or bismuth salts or proton-pump inhibitors in the last 2 months before the study, (3) chronic use of nonsteroidal anti-infl ammatory drugs or corticosteroids, (4) severe comorbid diseases, (5) gastric malignancy including adenocarcinoma and lymphoma; (6) pregnancy or lactation, (7) diarrhea, (8) prior gastric surgery, and (9) allergy to any of the drugs in the current treatment; (10) age under 18 years. Informed consent was obtained from each patient before enrolling into the study.
Th e patients were randomly divided into two groups. While ST group were given rabeprazole 20 mg (b.i.d, 30 minutes before meals) and amoxicillin 1000 mg (b.i.d, an hour after meals) for the fi rst 5 days of the treatment period and then rabeprazole 20 mg (b.i.d, 30 minutes before meals) clarithromycin 500 mg (b.i.d, an hour after meals) and metronidazole 500 mg (b.i.d, an hour after meals) in the remaining 5 days, bismuth plus ST (B+ST) group were given colloidal bismuth subcitrate 300 mg (equivalent to Bi 2 O 3 120 mg; two swallowed tablets, an hour before breakfast and dinner) for 10 days with the original ST. All patients continued rabeprazole 20 mg daily during the subsequent 30 days.
Th e detailed written treatment protocol was given to all patients to prevent misusage medications. Compliance was defi ned as being taken prescribed drugs more than 90. Th ey were actively interviewed about side eff ects and compliance using a structured questionnaire 1-week after the end of the treatment.
Th e primary endpoint of this study was to evaluate the eradication rate of 10 days bismuth containing ST (BST) therapy. Eradication rate was measured by urea breath test (UBT) at least 6 weeks after the end of the treatment. Th e C14-UBT was used for this purpose. Patients were informed about not using PPI, H2 receptor blocker, antibiotic and analgesic within 1-week before to UBT in order to avoid false negativity. After an overnight fasting, 37 kBq (1 mCi) of C14 urea/citric acid composition (Helicap, Noster System AB, Stockholm, Sweden) with 250 mL of water was given to patients orally. Breath samples were collected with a dry cartridge system (Heliprobe Breath Card, Noster System AB). A small desktop Geiger-Muller counter (Heliprobe analyzer, Noster System AB) was used for the analysis. Results were given both as counts per minute (CPM) and as grade (0: Not infected, CPM < 25; 1: Equivocal, CPM 25-50; 2: Infected, CPM > 50), as suggested by the manufacturer. Patients who remained positive for H. pylori after the initial treatment as determined by the C14 UBT were retreated with another rescue regimen.
Statistical analysis
Both "per protocol" (PP) (excluded patients with poor compliance of therapy and patients with unavailable data after therapy) and "ITT" (included all eligible patients enrolled into the study regardless of compliance with the study protocol; patients with unavailable data are assumed to have been unsuccessfully treated) analyses were used to evaluate H. pylori eradication rate. Data analysis was performed using Statistical Software Package Program (SPSS) version 16.0 (IBM, USA). Intergroup comparisons of categorical variables were done using Chi-square test and continuous variables were compared using Student' s t-test. Categorical variables were presented as percentages or counts and continuous variables were presented as mean and standard deviation in descriptive analysis. Results were evaluated at 95 of confidence interval (CI), and signifi cance was evaluated for each parameter at p < 0.05.
RESULTS
Treatment groups
A total of 150 patients were included in the ITT population (ST group, n = 75; B+ST group, n = 75). Table 1 shows baseline characteristics of the two ITT populations. Groups did not diff er with regard to demographical and clinical characteristics. Five patients were noncompliant to treatment protocol because of side eff ects. Th us, PP population consisted of 145 patients: Sequential therapy group, n = 73; bismuth plus ST group, n = 72. Major side eff ects were vomiting (n = 3) and abdominal pain (n = 2) ( Table 2) . Because of small case count per cells, statistical analysis could not be made in relation to side eff ects between groups. 
Treatment success
DISCUSSION
Th e result of our study indicated that the success of H. pylori eradication by using ST regimen with or without bismuth was not satisfactory in our region. In addition, it showed that addition of bismuth subcitrate to the ST regimen did not provide a signifi cant increase in eradication rates.
Th e major factor aff ecting the success rate of H. pylori eradication therapy is resistance to antibiotics. Resistance rate for clarithromycin has been reported as 8-30 and for metronidazole as 15-66 in the world [10] . Amoxicillin resistance has been reported as under 1. Since the presence of dual resistance theoretically removes both clarithromycin and metronidazole leaving only the PPI + amoxicillin dual regimen. Fourteen-day dual therapy with standard dose PPI provides approximately 50 of treatment success and approximately one-half that at 7 days [11] . Th erefore, ST is likely to be an unacceptable choice in regions where both clarithromycin and metronidazole resistance are common. Recently, in our region, metronidazole resistance was reported to be more than 40 and clarithromycin resistance was reported to be more than 30 [12] [13] [14] . So that ST is also not suitable treatment protocol for our region. Previous studies from our country are in accordance with our results [15] [16] .
Th ere is growing data about useful eff ects of bismuth compounds in H. pylori eradication treatment. Bismuth containing quadruple treatment has been showed to provide better eradication rates comparing to standard triple treatment [9] , and it has been recommended as a fi rst-line treatment in regions which have high clarithromycin rates [17] . However, it is unclear whether the addition of bismuth to all protocols in any way increases the eradication rate invariably or not. Th ere is some unconvincing data in the literature. One of these studies from our country which is conducted by Ergül et al., have reported high eradication rates (90.7) with the addition of bismuth to the standard triple regimen. However, they had not compared the same regimen without bismuth simultaneously [8] . Th ey have compared their results with previously reported data and showed a spectacular increase (nearly 30) in eradication rates. If these results were applicable generally, the eradication problem would have been solved by the addition of bismuth without the need for various antibiotic combinations. In addition, it has been known that success of H. pylori eradication varies according to race, region, virulence and impact of bacteria [18] . All these factors aff ect the homogeneity of the results. In another study from Turkey, Songür et al. [19] have showed no signifi cant diff erences in eradication rates between protocols which include lansoprazole, tetracycline, and metronidazole with or without bismuth.
Besides the PPI-based treatments which contain PPI, amoxicillin, clarithromycin and bismuth, ranitidine bismuth based treatments which contain ranitidine bismuth, amoxicillin, and clarithromycin have been also reported not to provide suffi cient success [20, 21] .
In our study, we did not found a signifi cant diff erence in eradication rates between the protocols with and without bismuth. Despite the undeniable eff ect of bismuth, there may be several possible reasons of unsatisfactory eradication success. Administration time of drugs is a very important factor, which infl uence the eff ectiveness. Bismuth has been reported to facilitate the passage of the antibiotic into the microorganism. Coadministration of bismuth compounds with antibiotics has been demonstrated to reduce antibiotic resistance or increase the eradication rates of antibiotic resistant strains [22] . In an in vitro study, bismuth has been found to act as synergistic eff ect with metronidazole and clarithromycin against antibiotic resistant H. pylori strains in agar dilution or E-test methodology using time-kill method [23] . A simple addition of bismuth compound to an antibiotic has been suggested not to overcome the established antibiotic resistance [24, 25] . However in the most applications, using of bismuth has been recommended before meal because of it acts at low pH and using of antibiotics have been recommended after meal because of their dyspeptic side eff ects. We also recommended our patients to use bismuth before meal. Since coadministration is more eff ective than simple addition, we may fail to demonstrate the real eff ect of bismuth. Bismuth salts are compounds that act topically. Less than 1 of the oral dose of commonly used bismuth compounds is absorbed. Its eff ect is pH dependent. In acidic pH, it is insoluble and forms complex polymers [26] . In this form, it is cytoprotective, it accumulates in ulcer crater and heal ulcer by preventing acid infl ux. It has also antibacterial eff ect by inhibiting of various enzymes produced by H. pylori -including urease, catalase, and lipase/phospholipase-; adhesion of H. pylori to surface epithelial cells; ATP synthesis; cell wall synthesis and membrane function [27, 28] . For these eff ects bismuth must be taken by bacteria. It has been shown that bismuth enter into the H. pylori cell, but the mechanism of the entrance is unclear [28, 29] . It has been suggested that bismuth may enter into the microorganism by diff usion or ion channel transport system [30] . In polymerized form, bismuth may not enter the microorganism and administration of bismuth in fasting condition may result in cytoprotective eff ect but not antibacterial eff ect. Th is practice may aff ect the bioavailability of the drug. In a study performed by Ciccaglione et al., bismuth had been administrated nearly after the meal time and they have shown 15 of favorable eff ect with addition of bismuth comparing to the same regimen without bismuth [7] .
Bismuth has been suggested to damage the H. pylori in different ways such as destroying glycocalyx wall [28] , DNA damage, competitive inhibition of bacterial enzymes. Although it has been suggested that H. pylori did not develop resistance against bismuth, compensatory changes have been reported in the microorganism after administration of bismuth. Nap A -a 150 kDa DNA-binding protein that protects cells from DNA damage -is found to be upregulated after administration of bismuth in vitro [31] . Although it has been suggested that bacteria can not gain resistance against destruction of glycocalyx wall, development of microbial resistance has been described in vitro for mutated microorganism which diminished production of glycocalyx [32] . Bismuth is from heavy metal class. It has been reported that bacteria could develop resistance to metals or show long-term adaptation [33] .
H. pylori has also various virulence factors to cope with the human systemic and local defense mechanisms, such fi ghting mechanisms of the bacteria may act in bismuth treatment. H. pylori response against to eff ects of bismuth is still unclear and likely to be the subject of further studies. However, over the time bismuth-based quadruple therapy has been showed to fail showing improvement in eradication rates comparing to standard triple treatment [34] .
Th e main limitation of the present study is the lack of any specifi c susceptibility testing for antibiotics. However, antibiotic susceptibility tests are not routinely performed in the fi rst-line eradication treatment of H. pylori regarding our study. Our primary outcome was to investigate whether there is a benefi cial eff ect of the addition of bismuth subcitrate to ST. Th is is the fi rst study which reported the eff ect of original ST with bismuth in H. pylori eradication. Further multicenter studies are needed with large sample size and without our limitations.
In conclusion, in areas with a high prevalence of metronidazole and clarithromycin resistance, the current formulation of ST is likely to provide grade F results. Although the published studies with ST conclusively and repeatedly demonstrated its superiority to legacy triple therapy and our results (74.6) are better than known eradication rates with triple therapy in our country (<60). It is not a suitable choice to consistently achieve grade A results. Moreover, the addition of bismuth subcitrate did not provide a benefi cial eff ect. Diversity in terms of drug administration or bacterial defense mechanism may have a role in this result.
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